FY2023 EPS Estimates for BioNTech SE Decreased by Analyst (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) – HC Wainwright dropped their FY2023 earnings estimates for shares of BioNTech in a report released on Tuesday, November 14th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of $4.68 for the year, down from their prior estimate of $8.24. HC Wainwright has a “Buy” rating and a $133.00 price target on the stock. The consensus estimate for BioNTech’s current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for BioNTech’s Q4 2023 earnings at $2.57 EPS, Q1 2024 earnings at $5.74 EPS, Q2 2024 earnings at ($1.86) EPS, Q3 2024 earnings at ($2.00) EPS, Q4 2024 earnings at $5.24 EPS and FY2024 earnings at $7.13 EPS.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.26. The firm had revenue of $895.30 million during the quarter, compared to analyst estimates of $850.50 million. BioNTech had a net margin of 41.09% and a return on equity of 13.15%. The company’s revenue was down 74.1% on a year-over-year basis. During the same quarter last year, the business posted $7.04 EPS.

A number of other equities research analysts have also issued reports on BNTX. Morgan Stanley lifted their target price on shares of BioNTech from $110.00 to $111.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. HSBC lowered shares of BioNTech from a “buy” rating to a “hold” rating and decreased their target price for the company from $124.00 to $111.00 in a research note on Monday, October 16th. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, BioNTech currently has a consensus rating of “Hold” and an average target price of $153.69.

BioNTech Trading Down 0.3 %

Shares of NASDAQ:BNTX opened at $99.39 on Friday. The firm has a fifty day moving average of $102.80 and a two-hundred day moving average of $107.35. The firm has a market capitalization of $23.63 billion, a P/E ratio of 8.62 and a beta of 0.28. BioNTech has a 12-month low of $88.00 and a 12-month high of $188.99. The company has a quick ratio of 10.14, a current ratio of 10.38 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Robeco Institutional Asset Management B.V. lifted its position in BioNTech by 178.8% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 74,733 shares of the company’s stock worth $9,309,000 after acquiring an additional 47,924 shares during the last quarter. B. Metzler seel. Sohn & Co. AG lifted its position in BioNTech by 1.4% during the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock worth $1,366,000 after acquiring an additional 150 shares during the last quarter. Sector Gamma AS lifted its position in BioNTech by 11.9% during the 1st quarter. Sector Gamma AS now owns 26,554 shares of the company’s stock worth $3,308,000 after acquiring an additional 2,816 shares during the last quarter. Duality Advisers LP acquired a new position in BioNTech during the 2nd quarter worth $3,387,000. Finally, Mackenzie Financial Corp lifted its position in BioNTech by 18.6% during the 2nd quarter. Mackenzie Financial Corp now owns 2,751 shares of the company’s stock worth $298,000 after acquiring an additional 431 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.